Get the Stockscreener App
83.18
2.00%
1.63
Metsera Inc stock is traded at $83.18, with a volume of 1.90M.
It is up +2.00% in the last 24 hours and up +57.24% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$81.55
Open:
$81.5
24h Volume:
1.90M
Relative Volume:
0.76
Market Cap:
$8.74B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+31.95%
1M Performance:
+57.24%
6M Performance:
+259.46%
1Y Performance:
+0.00%
1-Day Range:
$80.30
$83.86
1-Week Range:
$60.37
$83.86
52-Week Range:
$12.30
$83.86
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
83.18 | 8.58B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
View All
Metsera Inc Stock (MTSR) Latest News
Novo Nordisk says will not increase its proposal to acquire Metsera, Inc. - MarketScreener
Novo Nordisk will not increase its proposal to acquire Metsera, Inc. - GlobeNewswire
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Benzinga
Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk - MSN
Pfizer Sweetens Its Offer for Metsera in Bidding War Against Novo - MSN
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports - 1470 & 100.3 WMBD
Pfizer to Buy Metsera for $10 Billion, Capping Bidding War - Bloomberg.com
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle By Reuters - Investing.com
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle - Reuters
Pfizer Wins Metsera Bidding War Over Novo With Final $9B Price Tag - BioSpace
Pfizer beats out Novo in bidding war for obesity-drug startup Metsera - statnews.com
Pfizer and Metsera Reach Deal Expected to Top $10 Billion - The Wall Street Journal
Pfizer wins $10bn bidding war for weight-loss start-up Metsera - Financial Times
Metsera enters merger agreement with Pfizer - StreetInsider
Metsera says Pfizer to buy Metsera for up to $86.25 per share - MarketScreener
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer - MarketScreener
Pfizer sweetens offer for Metsera in bidding war against Novo - The Edge Malaysia
Metsera sale could be record size in weight loss universe - PitchBook
Metsera Enters Merger Agreement With Pfizer - US News Money
Pfizer, Novo risk overpaying in Metsera chase - Axios
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy - Benzinga
Metsera's complex choice between Novo and Pfizer - Axios
Pfizer sues Novo Nordisk and Metsera in bidding war - drugdiscoverytrends.com
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call - Yahoo Finance
How Metsera Inc. stock performs in stagflation2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Amid Metsera wrestling match, Novo CEO touts 'higher' bid and goads Pfizer - Fierce Biotech
Is Metsera Inc. stock a safe investment in uncertain marketsMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’ - BioSpace
Pfizer and Novo Nordisk’s battle over Metsera - Chemistry World
Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera - Yahoo Finance
Metsera weight-loss drug shows "excellent" tolerability in study - medwatch.com
Rx Rundown: Metsera, Pfizer, Eli Lilly and more - Medical Marketing and Media
Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera - Endpoints News
Weight-loss fever inspires epic battle of the pharma giants - The Times
Why Metsera Inc. stock appeals to analystsBear Alert & Verified Swing Trading Watchlists - newser.com
How currency fluctuations impact Metsera Inc. stockJuly 2025 News Drivers & Proven Capital Preservation Tips - newser.com
Novo Locks Horns With Pfizer Over Obesity Startup Metsera - Bloomberg.com
Historical volatility pattern of Metsera Inc. visualizedWeekly Stock Report & High Accuracy Trade Alerts - newser.com
This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed. - The Wall Street Journal
Novo Nordisk CEO challenges Pfizer on Metsera: "Put your hand in your pocket and bid higher" - medwatch.com
Metsera’s Impressive Clinical Data for Weight-Loss Drug Sparks Bidding War Among Pharma Giants - NAI500
Novo Nordisk Sweetens Bid for Obesity Drug Startup Metsera - Bloomberg.com
Metsera's Promising Weight Loss Drug Boosts Stock Amid Acquisiti - GuruFocus
Novo CEO says its bid for Metsera is higher - 104.1 WIKY
Pfizer, Novo again raise Metsera bids in intensifying obesity drug battle - Reuters
Watch Novo CEO Doustdar to Pfizer on Metsera Takeover Battle: ‘Bid Higher’ - Bloomberg.com
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera - Investor's Business Daily
Recon: FTC expresses concern over Novo Nordisk’s desire to buy Metsera; FDA OKs Caplyta as a add-on depression treatment - Regulatory Affairs Professionals Society | RAPS
Pfizer Matches Novo's $10B Metsera Bid, And Other Rumors - Law360
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):